Akademisyen profili · PROFESÖR
ABDURRAHMAN IŞIKDOĞAN
- Ana Dal Sağlık Bilimleri Temel Alanı
- Yan Dal Tıbbi Onkoloji (İç Hastalıkları)
- TIP FAKÜLTESİ
- DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
Scopus (SJR)
Q1
11
Q2
18
Q3
18
Q4
10
WoS (JCR)
Q1
4
Q2
9
Q3
19
Q4
20
TR Index
7
makale
Makaleler
- 2026 Aase-Smith syndrome type II
- 2025 Comparison of inflammatory indices in patients with metastatic non-small cell lung cancer
- 2025 Regional and Gender-Based Distribution of KRAS Mutations in Metastatic Colorectal Cancer Patients in Turkey: An Observational Study
- 2025 Survival of the Patients With Breast Cancer Who Underwent Oncotype DX Recurrence Score Testing: Long‐Term Survival Update of a Prospective Multicenter Study in Türkiye According to Different Cut‐Offs
- 2025 Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country
- 2025 Evaluation of treatment regimens and prognostic factors in primary central nervous system lymphomas
- 2024 The results of adding immunotherapy to chemotherapy in patients with small cell lung cancer: Registurk-Lung study—Real-world data
- 2024 Causes of liver test abnormalities in newly diagnosed cancer patients and the investigation of etiological factors
- 2024 The relationship between inflammation markers, positron emission tomography/computed tomography parameters and disease prognosis in advanced non-small-cell lung cancer patients
- 2024 The correlation between serum VEGF levels and known prognostic risk factors in colorectal carcinoma
- 2024 A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy
- 2023 Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices
- 2022 The effect of exercise on disease-free survival and overall survival in patients with breast cancer
- 2022 El papel pronóstico del SUVmáx basal y cambio del SUVmáx en la PET/TC con18F-FDG en pacientes con cáncer de mama con ganglios positivos que reciben quimioterapia neoadyuvante
- 2022 Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study
- 2022 Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy
- 2022 Thiol-disulphide Homeostasıs and Ischemia-modified Albumın Level and its Relatıonshıp with Clınicopathological Features of Breast Cancer
- 2022 The prognostic role of baseline 18F-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy
- 2022 A Low Body Fat Mass Ratio Predicts Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer
- 2022 Evaluation of factors predicting the effectiveness of regorafenib in the treatment of metastatic colorectal cancer